Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer

Fig. 1

Participation of WEE1 kinases (Cdk1 inhibitors) and CDC25 phosphatases (Cdk1 activators) in the regulation of the activity of Cdk1 kinase during G2 and M phases. The binding of WEE1 kinases to 14-3-3 protein, which activates WEE1 kinases, may be carried out in two different ways—via the phosphorylation of ser642 (with participation of CHK1) or autophosphorylation. WEE1 inhibitor abrogates the G2/M checkpoint, resulting in cancer cell death

Back to article page
\